TriSalus Life Sciences, Inc.
TLSI
Rank in Stocks
#16692
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the... TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
Share Price
$3.22
Last synced: 2026-11-09
Market Cap
$198.27M
Change (1 day)
-0.92%
Change (1 year)
-27.15%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade TriSalus Life Sciences, Inc. (TLSI)
Category
Healthcare
Operating Margin for TriSalus Life Sciences, Inc. (TLSI)
Operating Margin as of November 2026 TTM: -67.68%
According to TriSalus Life Sciences, Inc.'s latest financial reports, its current operating margin (TTM) is -67.68%. At the end of 2025 the company had an operating margin of -59.68%.
Operating Margin history for TriSalus Life Sciences, Inc. from 2020 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -67.68% | 13.40% |
| 2025 | -59.68% | -51.43% |
| 2024 | -122.88% | -58.24% |
| 2023 | -294.28% | 0.13% |
| 2022 | -293.91% | 2.74% |
| 2021 | -286.06% | 0.00% |
| 2020 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.24% | -100.23% |
US
|
|
| 18.08% | -100.27% |
IE
|
|
| 21.25% | -100.31% |
US
|
|
| 21.05% | -100.31% |
US
|
|
| 28.09% | -100.42% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about TriSalus Life Sciences, Inc.'s operating margin
What is TriSalus Life Sciences, Inc.'s operating margin?
TriSalus Life Sciences, Inc.'s operating margin is -67.68%, as of Nov 2026.
What was TriSalus Life Sciences, Inc.'s operating margin in 2025?
In 2025, TriSalus Life Sciences, Inc.'s operating margin was -59.68%, compared with -122.88% in 2024.
How has TriSalus Life Sciences, Inc.'s operating margin changed since 2020?
From 2020 to 2025, TriSalus Life Sciences, Inc.'s operating margin was highest in 2020 (0.00%) and lowest in 2023 (-294.28%).
How does TriSalus Life Sciences, Inc.'s operating margin compare with similar companies?
TriSalus Life Sciences, Inc.'s operating margin (-67.68%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 28.09%.